Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells

ABL tyrosine kinase inhibitors (TKI) like Imatinib, Dasatinib and Nilotinib are the gold standard in conventional treatment of CML. However, the emergence of resistance remains a major problem. Alternative therapeutic strategies of ABL TKI-resistant CML are urgently needed. We asked whether dual inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Illert, Anna L., Seitz, Anna K., Rummelt, Christoph, Kreutmair, Stefanie, Engh, Richard A., Goodstal, Samantha, Peschel, Christian, Duyster, Justus, von Bubnoff, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245092/
https://www.ncbi.nlm.nih.gov/pubmed/25426931
http://dx.doi.org/10.1371/journal.pone.0112318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245092/
https://www.ncbi.nlm.nih.gov/pubmed/25426931
http://dx.doi.org/10.1371/journal.pone.0112318

Ejemplares similares